The use of tumor markers in ovarian Oncology

Oncology is a very common problem. There are many variants of this disease. The malignant process can affect the various organs and structures in the body. Early diagnosis of cancer can save the patient's life. For diagnosis of the disease besides used tests for tumor markers (substances in the body, the concentration of which can be suspected in humans, cancer or other diseases). 100% accurately diagnose cancer by using tumor markers is impossible, but the repetition of the analysis allows to suggest the presence of cancer or other disease. Differential diagnosis needs to conduct additional research.

The tumor marker CA-125

To diagnose some forms of cancer used CA-125 tumor marker. This glycoprotein, which is found in the tissues of ovary, kidney, pancreas, gall bladder, stomach, intestines and bronchi. In the diagnosis of cancer of these bodies can be used, but such analysis is not recommended due to low specificity of tumor markers and the lack of sensitivity in the early stages of the disease. The main use of CA-125 tumor marker found in the diagnosis of ovarian cancer.

Tumor markers used in ovarian cancer in women with a genetic predisposition to developing ovarian cancer and breast cancer. Also the tumor marker CA-125 is recommended as a screening test for women after the onset of menopause.

Other diseases

The greatest application changes in the level of the glycoprotein CA-125 is found in monitoring the effectiveness of therapy, prognosis for the patient with cancer and identify the risk of the formation of recurrence and metastasis. In addition to Oncology, the tumor marker used to evaluate the effectiveness of treatment.

Also the tumor marker CA-125 is recommended for the diagnosis of cancer of the pancreas along with the tumor marker CA 19-9). These tumor markers in the ovarian cyst is also recommended. They allow to diagnose the disease and monitor the effectiveness of its treatment.

Can also be applied to tumor markers for ovarian optionally, the detection masses in the pelvis.

Analysis

The analysis is performed using blood sampling from a vein of the patient. The type of immunochemical analysis. Preparation for analysis involves the observance of certain rules. For analysis it is important to choose the right day, in consultation with the menstrual cycle. Optimum is analysis on day 5-7 from the beginning of the menstrual cycle.

Before the test for 8 hours do not eat, smoke. The liquid can be consumed, but to exclude carbonated beverages, coffee, tea and alcohol. 3 days before the analysis it is better not to eat too fatty foods.

Not recommended significant physical exertion, especially just before taking analysis. The patient refuse to recommend various drug treatments prior to analysis. They can affect the result of the analysis (even massage should not be performed). The medication should be agreed with the doctor. Perhaps they should give up.

Blood sampling occurs in the morning on an empty stomach. Blood after capture should be properly stored (no more than 2 hours after collection from the patient).

Transcript analyses

The rate of ovarian tumor markers is up to 35 IU/ml. Elevated concentrations of tumor marker in blood serum (120-165 IU/ml) was observed in not less than than 80% of women with ovarian cancer. The stage of disease and type of cancer is also important and different for different types of cancer.

In deciphering analyses shouldnote that the elevated tumor markers of ovaries may occur under the following conditions and pathologies:

• endometriosis;
• ovarian cysts;
• inflammatory diseases of the appendages, liver, abdominal cavity);
• menstruation and pregnancy (3rd trimester);
• hepatitis and cirrhosis of the liver;
• autoimmune diseases.

Can also be other reasons for changes in the concentration of tumor markers in the blood of the patient. Because the physician must be experienced. His attentive attitude to the patient will allow you to diagnose various pathologies and begin appropriate treatment. Low efficiency of therapy, which are evaluated in terms of tumor markers, can affect the choice of treatment doctor, change the techniques of therapeutic effects on the disease.